Automate Your Wheel Strategy on PODD
With Tiblio's Option Bot, you can configure your own wheel strategy including PODD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PODD
- Rev/Share 33.549
- Book/Share 20.8019
- PB 15.4155
- Debt/Equity 0.9568
- CurrentRatio 2.2569
- ROIC 0.1408
- MktCap 22571355125.0
- FreeCF/Share 4.1362
- PFCF 77.5915
- PE 82.5149
- Debt/Assets 0.4035
- DivYield 0
- ROE 0.2134
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PODD | Truist | -- | Buy | -- | $365 | June 16, 2025 |
| Initiation | PODD | Goldman | -- | Buy | -- | $380 | May 30, 2025 |
| Upgrade | PODD | Wolfe Research | Peer Perform | Outperform | -- | $350 | May 13, 2025 |
| Downgrade | PODD | Wolfe Research | Outperform | Peer Perform | -- | -- | April 29, 2025 |
| Initiation | PODD | RBC Capital Mkts | -- | Outperform | -- | $340 | March 6, 2025 |
News
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
Read More
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Insulet Corporation (NASDAQ:PODD ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Ana Maria Chadwick - Executive VP & CFO Ashley A. McEvoy - CEO, President & Director Eric Benjamin - Executive VP, Chief Product & Customer Experience Officer June Lazaroff - Senior Director of Investor Relations Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Issie Kirby - Redburn (Europe) Limited, Research Division Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Jeffrey D.
Read More
Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet (PODD) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.55 per share a year ago.
Read More
Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why You Should Retain PODD Stock in Your Portfolio Now
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.
Read More
Here's Why Insulet (PODD) is a Strong Growth Stock
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
S&P 500 Wraps Up Best May Since 1990: 5 Top Stocks in the ETF
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
SPY jumped 6.3% in May, the most in decades, led by standout gains in NRG, STX, CEG, PODD and MCHP amid easing trade fears.
Read More
Insulet Gains 78.5% in a Year: What's Driving the Stock?
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.
Read More
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available followin.
Read More
4 Medical Product Stocks to Watch From a Challenging Industry
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Negative
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
Read More
Here's Why Insulet (PODD) is a Strong Momentum Stock
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.
Read More
Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More
Published: May 09, 2025 by: Investopedia
Sentiment: Neutral
U.S. equities were mixed and little changed at midday as the markets awaited key trade talks between the U.S. and China set for this weekend. The Dow Jones Industrial Average edged lower, while the S&P 500 and Nasdaq were slightly higher.
Read More
Insulet Is the Top S&P 500 Performer Today. Here's Why.
Published: May 09, 2025 by: Barrons
Sentiment: Positive
The insulin pump maker beat earnings expectations for the first quarter and raised its forecast for 2025.
Read More
Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Insulet Corporation (NASDAQ:PODD ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director, IR Tim Scannell - Chair Ashley McEvoy - President and CEO Ana Chadwick - EVP and CFO Eric Benjamin - Chief Product and Customer Experience Officer Conference Call Participants Travis Steve - Bank of America Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Patrick Wood - Morgan Stanley Marie Thibault - BTIG Michael Polark - Wolfe Research Matt O'Brien - Piper Sandler Steve Lichtman - Oppenheimer Issie Kirby - …
Read More
Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Read More
4 Medical Product Stocks to Buy From a Challenging Industry
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
Read More
PODD Stock Benefits From the Launch of Omnipod 5 in Canada
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.
Read More
PODD Stock Gains Following the Launch of Omnipod 5 in Australia
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.
Read More
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.
Read More
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
Published: February 21, 2025 by: Benzinga
Sentiment: Positive
On Thursday, Insulet Corporation PODD reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02.
Read More
Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Insulet Corporation (NASDAQ:PODD ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director of Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Chadwick - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Robert Marcus - JPMorgan Jeffrey Johnson - Baird Travis Steed - Bank of America Michael Polark - Wolfe Research Issie Kirby - Redburn Atlantic Patrick Wood - Morgan Stanley Macauley Kilbane - William Blair Larry Biegelsen - Wells Fargo Marie Thibault - BTIG Mike Kratky - Leerink Partners Jayson Bedford - Raymond James …
Read More
About Insulet Corporation (PODD)
- IPO Date 2007-05-15
- Website https://www.insulet.com
- Industry Medical - Devices
- CEO Ashley A. McEvoy
- Employees 3900